Who
Erik Ostrowski
SVP, CFO, CBO & Treasurer
Company insider
Files Form 4 as: SVP, CFO, CBO & Treasurer, Akebia Therapeutics; Interim CEO, President and CFO, Tectonic Therapeutic.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $373K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Jan 2019
- Last trade
- 29 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 1 Jul 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $62K56,019 at $1.11 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $62K56,019 at $1.11 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $49K34,951 at $1.39 | filing |
| 2 Feb 2026filed 4 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $49K34,951 at $1.39 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —320,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —204,000 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Sold | $152K41,314 at $3.67 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —292,300 at $0.00 | filing |
| 31 Jan 2025filed 4 Feb 2025 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —194,900 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | AKBA Akebia Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | AKBA Akebia TherapeuticsPharmaceuticals | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 5 Feb 2024filed 5 Feb 2024 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $16K13,099 at $1.20 | filing |
| 1 Feb 2024filed 5 Feb 2024 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,084 at $0.00 | filing |
| 1 Feb 2024filed 5 Feb 2024 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code M | —40,084 at $0.00 | filing |
| 1 Jul 2023filed 3 Jul 2023 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 8 Feb 2023filed 10 Feb 2023 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,333 at $0.00 | filing |
| 8 Dec 2022filed 9 Dec 2022 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —221,000 at $0.00 | filing |
| 2 Feb 2022filed 4 Feb 2022 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
News
Analyzing Akebia Therapeutics (NASDAQ:AKBA) and Pharming Group (NASDAQ:PHAR)AKBA · tickerreport.com · 18 Oct 2026Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health ForumAKBA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Erik Ostrowski; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.